Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
1.710
+0.070 (4.27%)
Jan 22, 2026, 9:51 AM EST - Market open
Ovid Therapeutics Employees
Ovid Therapeutics had 23 employees as of December 31, 2024. The number of employees decreased by 17 or -42.50% compared to the previous year.
Employees
23
Change (1Y)
-17
Growth (1Y)
-42.50%
Revenue / Employee
$287,391
Profits / Employee
-$1,559,652
Market Cap
222.62M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 23 | -17 | -42.50% |
| Dec 31, 2023 | 40 | -4 | -9.09% |
| Dec 31, 2022 | 44 | -13 | -22.81% |
| Dec 31, 2021 | 57 | -10 | -14.93% |
| Dec 31, 2020 | 67 | 8 | 13.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OVID News
- 5 weeks ago - Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) - GlobeNewsWire
- 7 weeks ago - Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Ovid Therapeutics Inc. - Special Call - Seeking Alpha
- 3 months ago - Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds - GlobeNewsWire
- 3 months ago - Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile - GlobeNewsWire
- 5 months ago - Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference - GlobeNewsWire